{
    "name": "faricimab",
    "comment": "Rx",
    "other_names": [
        "Vabysmo",
        "faricimab-svoa"
    ],
    "classes": [
        "Ophthalmics",
        "VEGF Inhibitors",
        "Ophthalmics",
        "ANG-2 Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/vabysmo-faricimab-4000244",
    "pregnancy": {
        "common": [
            "There are no adequate and well-controlled studies on use in pregnant females",
            "Do not use during pregnancy unless potential benefit to patient outweighs potential risk of fetus"
        ],
        "specific": [
            {
                "type": "Contraception",
                "description": [
                    "Females of reproductive potential: Use effective contraception before initiating, during treatment, and for â‰¥3 months following last dose"
                ]
            },
            {
                "type": "Infertility",
                "description": [
                    "No studies conducted and unknown whether faricimab can affect reproduction capacity",
                    "Based on mechanism of action, treatment may pose a risk to reproductive capacity"
                ]
            },
            {
                "type": "Animal data",
                "description": [
                    "IV administration to pregnant monkeys during organogenesis resulted in an increased incidence of abortions at doses 158x the human exposure",
                    "Based on mechanism of action of VEGF and angiopoietin-2 (Ang-2) inhibitors, there is potential risks to female reproductive capacity and embryofetal development"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There is no information regarding presence of faricimab in human milk, its effects on breastfed infants, or its effects on milk production",
            "Many drugs are transferred in human milk with potential for absorption and adverse reactions in breastfed children"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Ocular or periocular infection",
                "Active intraocular inflammation",
                "Hypersensitivity to faricimab or excipients"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Endophthalmitis and retinal detachments may occur following intravitreal injection; instruct patients to report any symptoms suggestive of endophthalmitis or retinal detachment (eg, vision loss, eye pain, eye redness, photophobia, blurred vision) without delay, to treat promptly and appropriately",
                "Increases in intraocular pressure observed within 60 minutes of administration",
                "Potential risk of arterial thromboembolic events (ATEs) associated with vascular endothelial growth factor (VEGF) inhibition; ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause)"
            ],
            "specific": []
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Conjunctival hemorrhage",
            "percent": "7"
        },
        {
            "name": "Vitreous floaters",
            "percent": "3"
        },
        {
            "name": "Retinal pigment epithelial tear",
            "percent": "3"
        },
        {
            "name": "Intraocular pressure increased",
            "percent": "3"
        },
        {
            "name": "Eye pain",
            "percent": "3"
        },
        {
            "name": "Intraocular inflammation",
            "percent": "2"
        },
        {
            "name": "Eye irritation",
            "percent": "1"
        },
        {
            "name": "Ocular discomfort",
            "percent": "1"
        },
        {
            "name": "Conjunctival hemorrhage",
            "percent": "7"
        },
        {
            "name": "Vitreous floaters",
            "percent": "3"
        },
        {
            "name": "Intraocular pressure increased",
            "percent": "3"
        },
        {
            "name": "Eye pain",
            "percent": "2"
        },
        {
            "name": "Intraocular inflammation",
            "percent": "1"
        },
        {
            "name": "Eye irritation",
            "percent": "1"
        },
        {
            "name": "Ocular discomfort",
            "percent": "1"
        },
        {
            "name": "Vitreous hemorrhage",
            "percent": "1"
        },
        {
            "name": "Vitreous hemorrhage",
            "percent": "1"
        }
    ]
}